Affinity Asset Advisors, LLC Arca Biopharma, Inc. Put Options Transaction History

Affinity Asset Advisors, LLC

  • $579 Million
  • Q3 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding ABIO

# of Institutions
2
Shares Held
280K
Call Options Held
0
Put Options Held
0
View Full List

About ARCA biopharma, Inc.

ABIO Quotes by TradingView
  • Ticker ABIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,410,100
  • Description
  • ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...
More about ABIO
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email